Decreased proinflammatory cytokines production in children with complicated parapneumonic pleural effusion after intrapleural fibrinolytic treatment

Research output: Contribution to journalArticle

Abstract

Intrapleural fibrinolytic therapy (IFT) provides clinical benefit in the treatment of complicated pleural parapneumonic effusion (CPE). Whether IFT influences the proinflammatory cytokines production and fibrinlytic activity is currently unclear. Therefore, we collected pleural effusion samples from CPE patients with IFT (study group) and patients without IFT (control group). A membrane human inflammatory cytokines array kit was used to compare the difference of targeted cytokine production between these two groups. Enzyme-linked immunosorbent assay (ELISA) methods were used for quantitative analysis of targeted cytokines and fibrinolytic enzymes. The results showed there were no significant differences between the study (n = 16) and control (n = 14) groups in patients' demographic data. After fibrinolytic therapy, the patients in the study group had significant lower plasminogen activator inhibitor (PAI) level (732.36/±/254.09 ng/mL vs 1,509.36/±/1,340. 11 ng/mL, p/</0.05) and higher urokinase plasminogen activator (u-PA) level (75.56/±/41.70 ng/mL vs 6.87/±/5.07 ng/mL, p/</0.05) than they did before treatment. Moreover, the tissue inhibitors of metalloproteinase-2 (TIMP-2) (1,560.03/±/403.49 pg/mL vs 3,686.45/±/1,263.83 pg/mL, p/</0.05) and inflammatory chemokine, regulated on activation normal T-cell expressed and secreted/chemokine (C-C motif) ligand 5 (RANTES), (293.58/±/212.93 pg/mL vs 749.27/±/53.79 pg/mL, p/</0.05), were also significantly lower in the study group after fibrinolytic therapy, but not in the control group. In conclusion, intrapleural fibrinolytic treatment with urokinase could enhance fibrinolytic activity and decrease TIMP-2 and RANTES production.

Original languageEnglish
Pages (from-to)410-418
Number of pages9
JournalInflammation
Volume32
Issue number6
DOIs
Publication statusPublished - 2009 Dec 1

Fingerprint

Thrombolytic Therapy
Pleural Effusion
Cytokines
Tissue Inhibitor of Metalloproteinase-2
Chemokine CCL5
Urokinase-Type Plasminogen Activator
Therapeutics
Plasminogen Inactivators
CC Chemokines
Control Groups
Tissue Inhibitor of Metalloproteinase-1
Plasminogen Activators
Chemokines
Enzyme-Linked Immunosorbent Assay
Demography
Ligands
T-Lymphocytes
Membranes
Enzymes

All Science Journal Classification (ASJC) codes

  • Immunology
  • Immunology and Allergy

Cite this

@article{814029863c2e49a1b6ea985072743737,
title = "Decreased proinflammatory cytokines production in children with complicated parapneumonic pleural effusion after intrapleural fibrinolytic treatment",
abstract = "Intrapleural fibrinolytic therapy (IFT) provides clinical benefit in the treatment of complicated pleural parapneumonic effusion (CPE). Whether IFT influences the proinflammatory cytokines production and fibrinlytic activity is currently unclear. Therefore, we collected pleural effusion samples from CPE patients with IFT (study group) and patients without IFT (control group). A membrane human inflammatory cytokines array kit was used to compare the difference of targeted cytokine production between these two groups. Enzyme-linked immunosorbent assay (ELISA) methods were used for quantitative analysis of targeted cytokines and fibrinolytic enzymes. The results showed there were no significant differences between the study (n = 16) and control (n = 14) groups in patients' demographic data. After fibrinolytic therapy, the patients in the study group had significant lower plasminogen activator inhibitor (PAI) level (732.36/±/254.09 ng/mL vs 1,509.36/±/1,340. 11 ng/mL, p/",
author = "Jieh-Neng Wang and Jhy-Wei Shin and Chang, {Tsuey Yu} and Jiu-Yao Wang and Jing-Ming Wu",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/s10753-009-9150-2",
language = "English",
volume = "32",
pages = "410--418",
journal = "Inflammation",
issn = "0360-3997",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Decreased proinflammatory cytokines production in children with complicated parapneumonic pleural effusion after intrapleural fibrinolytic treatment

AU - Wang, Jieh-Neng

AU - Shin, Jhy-Wei

AU - Chang, Tsuey Yu

AU - Wang, Jiu-Yao

AU - Wu, Jing-Ming

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Intrapleural fibrinolytic therapy (IFT) provides clinical benefit in the treatment of complicated pleural parapneumonic effusion (CPE). Whether IFT influences the proinflammatory cytokines production and fibrinlytic activity is currently unclear. Therefore, we collected pleural effusion samples from CPE patients with IFT (study group) and patients without IFT (control group). A membrane human inflammatory cytokines array kit was used to compare the difference of targeted cytokine production between these two groups. Enzyme-linked immunosorbent assay (ELISA) methods were used for quantitative analysis of targeted cytokines and fibrinolytic enzymes. The results showed there were no significant differences between the study (n = 16) and control (n = 14) groups in patients' demographic data. After fibrinolytic therapy, the patients in the study group had significant lower plasminogen activator inhibitor (PAI) level (732.36/±/254.09 ng/mL vs 1,509.36/±/1,340. 11 ng/mL, p/

AB - Intrapleural fibrinolytic therapy (IFT) provides clinical benefit in the treatment of complicated pleural parapneumonic effusion (CPE). Whether IFT influences the proinflammatory cytokines production and fibrinlytic activity is currently unclear. Therefore, we collected pleural effusion samples from CPE patients with IFT (study group) and patients without IFT (control group). A membrane human inflammatory cytokines array kit was used to compare the difference of targeted cytokine production between these two groups. Enzyme-linked immunosorbent assay (ELISA) methods were used for quantitative analysis of targeted cytokines and fibrinolytic enzymes. The results showed there were no significant differences between the study (n = 16) and control (n = 14) groups in patients' demographic data. After fibrinolytic therapy, the patients in the study group had significant lower plasminogen activator inhibitor (PAI) level (732.36/±/254.09 ng/mL vs 1,509.36/±/1,340. 11 ng/mL, p/

UR - http://www.scopus.com/inward/record.url?scp=70449411534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449411534&partnerID=8YFLogxK

U2 - 10.1007/s10753-009-9150-2

DO - 10.1007/s10753-009-9150-2

M3 - Article

VL - 32

SP - 410

EP - 418

JO - Inflammation

JF - Inflammation

SN - 0360-3997

IS - 6

ER -